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Background: The molecular heterogeneity of high-grade astrocytomas underlies the difficulties in the development
of representative and valuable in vitro experimental models for their studies.
The purpose of our study was to estimate the value of astrocytoma-associated antigens (AAAs) - IL13Rα2, Fra-1,
EphA2 - and the most common molecular aberrations typical for astrocytomas as potential markers to screen the
status of tumour-derived cell cultures in vitro.
Methods: The tumour-derived cell cultures were established from high-grade astrocytomas. The expression
analyses of the tested genes were performed via semi-quantitative real-time PCR and subsequently verified by
immunohistochemical and immunocytochemical technique. The analyses of molecular aberrations at DNA level
included gene dosage status evaluation based on real-time PCR, sequencing analysis, and loss of heterozygosity
(LOH) assay.
Results: The expression analyses based on semi-quantitative real-time PCR showed that in the final stage of culture
the expression level of all tested AAAs was significantly higher or at least comparable to that of primary tumours;
however, two expression patterns were observed during cell culture establishment. Analysis at the single cell level via
immunocytochemistry also demonstrated an increase of the level of tested proteins and/or selection of tumour cell
populations strongly positive for AAAs vs. other cell types including admixed non-tumoural cells. Confrontation of AAA
expression data with the results of molecular analyses at DNA level seems to support the latter, revealing that the
expression pattern of astrocytoma-associated antigens in tumour-derived cells in subsequent stages of culture is
convergent with changes in the molecular profile of examined cell populations.
Conclusions: The consistency of the obtained results seems to support the use of the selected AAAs, in particular
IL13Rα2 and Fra-1, as tools facilitating the establishment of tumour-derived cultures. However, the intratumoural
heterogeneity of high-grade astrocytomas may require further detailed characterisation of the molecular profile of a
tumour in order to evaluate the value of the experimental model in relation to the individual context of particular
studies.
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Figure 1 Basic histological characteristics of representative
astrocytoma sections. Histological pattern of one of the
glioblastoma cases showing cellular pleomorphism, palisade necrosis
(arrow) and microvascular proliferations (short arrows) (a). G112
tumour did not show any areas of necrosis or microvascular
proliferations. Cells with pleomorphic nuclei and mitotic activity
were strongly GFAP immunoreactive thus it was classified as WHO
grade III (b).
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Tumour-derived cell cultures are a common model used
for studies including tumourigenesis, signalling pathway
dysregulation, mechanisms of drug resistance or the
search for new therapeutic approaches.
Nevertheless, there is a controversy regarding the feasi-
bility of development a representative model in artificial
in vitro conditions and the utility of tumour-derived cell
lines. Several recent reports discuss this issue with regard
to glioma-derived cells cultured in the various experimen-
tal conditions [1-6].
We report here an attempt to exploit tumour-associated
antigens as simple tools to characterize the status of
astrocytoma-derived cell cultures and indicators of pres-
ence of neoplastic cells during cell culture establishment.
Based on previously published data, astrocytoma-asso-
ciated antigens (AAAs), such as Interleukin-13 Receptor
α2 (IL13Rα2), Fos-Related Antigen 1 (Fra-1), and EphA2
receptor tyrosine kinase (EphA2) were selected. These an-
tigens had been described as molecular denominators of
high-grade astrocytomas and potential novel therapeutic
targets [7-14]. Additionally, the most frequent molecular
abnormalities presented in astrocytomas (LOH 10p and
LOH 10q; TP 53 mutations; EGFR amplification/chromo-
some 7 polysomy; EGFRvIII variant; CDKN2A deletions;
IDH1 mutations) were used as markers of neoplastic cells
at the DNA level [15-18].
Results
Characteristics of astrocytoma tumours exploited for
generation of cell cultures
Initially, seven astrocytoma samples were used to obtain
the cell cultures. However, in two cases the culture
growth was not effective. Astrocytoma cells derived from
remaining four cases had been cultured successfully for
up to 5–7 months. In a case of the newest sample, this
process took up to 3–4 months. Then, all cultures were
terminated. Material for further analyses was collected
three times: at the early (1–2 months), middle (3–4
months) and late (5–7 months) stages of cell culture, de-
pending on the proliferation ability of cells derived from
particular tumours.
The general description of tumours including basic
clinical data and histopathological characteristics were
compiled in Table 1 and Figure 1.Table 1 Basic clinical characteristics
Sample Histopathology Age Se
G 108 Glioblastoma 59 F
G 111 Glioblastoma 50 F
G 112 Anaplastic astrocytoma 58 M
G 113 Glioblastoma 73 F
G 114 Glioblastoma 65 MThe molecular profile of tumours exploited to estab-
lish cell culture were characterised initially with regard
to the most common abnormalities occurring in astrocy-
tomas: TP 53 mutational status, EGFR copy number &
chromosome 7 polysomy, EGFRvIII presence, CDKN2A
status, loss of heterozygosity on 10p and 10q, and IDH1
mutational status. Table 2 presents the molecular cha-






Table 2 Molecular characteristics of initial tumour samples
Sample TP53 EGFR amp./ch. 7 polys. EGFRvIII CDKN2A LOH 10p LOH 10q IDH1
G 108 MT Ex 8, 262, GGT→ GTT A/P - DEL LOH LOH -
G 111 WT A - DEL LOH LOH -
G 112 WT A - DEL LOH LOH -
G 113 WT Low A - - ROH ROH -
G 114 WT Low A - DEL NI LOH -
MT =mutation, changes in nucleotide sequences are indicated by arrows; WT = wild type; A = amplification; P = polysomy; low A = amplification at low level;
DEL = deletion; LOH = loss of heterozygosity; ROH = retention of heterozygosity; NI = non informative.
Witusik-Perkowska et al. Cancer Cell International 2014, 14:82 Page 3 of 12
http://www.cancerci.com/content/14/1/82Moreover, the original tumours were evaluated concern-
ing astrocytoma-associated antigens expression (IL13Rα2,
Fra-1 and EphA2) using the real-time PCR method
(Figure 2). In comparison to a control, which was repre-
sented by commercially available RNA from normal hu-
man brain, our results demonstrated an overexpression of
IL13Rα2 in all tested samples, a significantly higher level
of Fra-1 in four samples (G108, G112, G113, G114) and a
significantly higher expression of EphA2 in two samples
(G111, G113), (P < 0.05). One sample (G111) presented an
expression of Fra-1 comparable to that reported for a nor-
mal brain. The expression of EphA2 was similar to that of
a normal brain in the G112 sample and even lower in two
other tested samples - G108 and G114 (P < 0.05). Ad-
ditionally, immunohistochemical analyses were performed
for two antigens (IL13Rα2, Fra-1) overexpressed at mRNA
level in the majority of the original tumours (Figure 3).
Strong membrane and cytoplasmic reactivity for IL13Rα2
was found in three tumour sections, and weak cytoplasmic
staining was observed in two other cases (Figure 3a-e). Nu-
clear immunoreactivity for Fra-1 was observed in three
tumour sections, and one sample presented weak cytoplas-
mic expression pattern (Figure 3g-k).
The study at the mRNA level showed that in four of





















Figure 2 Evaluation of Il13Rα2, Fra-1, and EphA2 expression
in initial tumours at the mRNA level. Results of real-time PCR
(means ± SD) enabled the identification of tumours exhibiting
overexpression of astrocytoma-associated antigens. BT = normal
brain tissue; G108-G114T = particular tumour samples.astrocytoma-associated antigens occurred. The IL13Rα2
immunoreactivity was found in all tested tumour speci-
mens, while Fra-1 antigen was detected in four tested
samples.Astrocytoma-derived cell cultures presented an increasing
level of tumour –associated antigens
The expression of astrocytoma-associated antigens
(IL13Rα2, Fra-1, and EphA2) in particular stages of as-
trocytoma-derived cultures was assessed both at the
mRNA and protein levels.
The results of real-time PCR demonstrated a gradual
increase in the expression of all tested astrocytoma-
associated antigens during particular stages of cell culture
for the G108 and G114 samples. In the final step of cul-
ture, the expression of the tested genes was significantly
higher than that observed in original tumours (P < 0.05),
(Figure 4a). In three of the tested cases (G111, G112, and
G113), a transient decrease in the tested genes expression
in the first step of culture (1–2 months) was observed in
comparison to the original tumour tissue (P < 0.05). Sub-
sequently, the expression increased, finally reaching the
level observed in the original tumour or higher (P < 0.05),
(Figure 4b). In one case, a fluctuation of EphA2 level was
detected in the final stage of G112 culture. This observa-
tion was interpreted as a subtle downregulation of expres-
sion observed after 5–7 months of culture in comparison
to the 3–4 month step (P < 0.05). However, the EphA2
mRNA level was still significantly higher than that de-
tected in the original tumour (P < 0.05). Since real-time
PCR method enables the assessment of gene expression in
the whole population of tested cells, our results were veri-
fied at the single cell level by immunocytochemistry tech-
nique. The results confirmed those observed at the
mRNA level, demonstrating the expansion of cell popula-
tions positive for AAAs and/or increased expression of
the tested genes. Figure 5 depicts the representative results
of immunocytochemistry demonstrating changes of AAA
levels in the G113-derived culture. Additionally, the im-
munocytochemical data revealed that overexpression of
the Fra-1 antigen in astrocytoma cells can be manifested
by the cytoplasmic and nuclear localisation of this protein
Figure 3 Immunohistochemical analysis of Il13Rα2 and Fra-1 expression in initial tumours. The IL13Rα2 immunoreactivity was observed in
all tested tumour specimens (a-e); Fra-1 antigen was detected in four tested samples (g-k); negative controls (f, l).
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levels seem to be more subtle than that reported for
IL13Rα2 and Fra-1 (Figure 5c). This finding is consistent
with real-time PCR data demonstrating the relatively low
expression level of this antigen in the tested astrocytoma
specimens (Figure 4).
As a positive control for AAA expression analyses
both at mRNA and protein levels, the U87MG cell line
was used (Figure 4, Figure 5d).
Utility of the selected molecular hallmarks of
astrocytomas as markers of tumour cells in vitro
The initial molecular characteristics of astrocytoma samples
enabled the selection of anomalies presented in primary
tumours which could be further analysed in subsequent
stages of astrocytoma-derived culture (Table 2).The comparative analysis of initial tumours vs. cells col-
lected from particular stages of culture in relation to the
loss of heterozygosity on chromosome 10p and 10q is pre-
sented in Figure 6. The results demonstrated that positive
selection of cells harbouring these anomalies in vitro be-
came visible at middle/final stages of culture. Additionally,
in one case (G113), we identified LOH 10p and LOH 10q
at middle/final stages of culture, while these anomalies
were not detected in the original tumour.
The CDKN2A status was monitored with the use of
real-time PCR at the DNA level (Table 3). The results
showed that deletion of the CDKN2A gene was propa-
gated in vitro. Moreover, the data revealed a gradual de-
crease in a gene dosage level in subsequent passages of
culture (G111, G112, G114), suggesting the positive se-
lection of cell populations with this aberration.
Figure 4 Analysis of Il13Rα2, Fra-1, and EphA2 expression in astrocytoma-derived cell cultures at the mRNA level. Results of real-time
PCR (means ± SD) demonstrated two patterns of of AAA expression during particular stages of cell culture - a gradual increase of the AAA mRNA
levels for G108 and G114 (a) and transient decrease of the AAA expression in the first step of culture (1-2 months) for G111, G112, and G113
samples (b). U87MG was used as positive control. BT = normal brain tissue; G108T-G114T = initial tumour samples.
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PCR revealed a decline in EGFR amplification in vitro to
a very low level that was closed to the threshold value
assumed for this method (Table 4). EGFR gene over-
dosage resulting from chromosome 7 polysomy was de-
tected in the G108 sample both in initial tumour and
subsequent passages of culture. In one case (G114), a
relatively stable, but low level of EGFR gene overdosage
in vitro was observed, despite the fact that chromosome
7 polysomy was not identified in this sample.
Mutational analysis of the TP53 gene revealed a muta-
tion in the G108 tumour propagated along with all steps
of culture. In two cases (G113, G114), TP53 mutations
were detected in vitro only in all stages of cell culture
(Table 5).
Discussion
Interleukin-13 Receptor α2, Fos-Related Antigen 1, and
EphA2 receptor tyrosine kinase are considered as astro-
cytoma-associated antigens (AAAs) and potential thera-
peutic targets [7-14]. In this paper, the utility of theseproteins as potential markers facilitating the monitoring
of the status of astrocytoma-derived cell cultures in vitro
was determined. Initial evaluation, performed by a semi-
quantitative real-time PCR method, revealed that all ex-
amined tumours displayed overexpression of at least one
of the selected astrocytoma-associated antigens and four
of the five tested samples demonstrated a significantly
higher level of two of AAAs in comparison to that
reported for a normal brain. The analyses verified subse-
quently at the protein level showed the IL13Rα2 immuno-
reactivity in all tumour specimens, and Fra-1 antigen in
four of the five examined samples. The results obtained
in this study are consistent with previously reported im-
munohistochemical findings [7]. Moreover, comparative
analyses of AAA levels during particular stages of cell cul-
ture were also performed in the present study. The results
of analyses at the mRNA level showed that the expression
of all tested AAAs in the final stage of culture was signifi-
cantly higher or comparable to the levels detected in pri-
mary tumours. However, two expression patterns during
cell culture establishment were observed. Additionally, the
Figure 5 Expression of astrocytoma-asociated antigens in the representative tumour-derived cell culture (G113). Immunocytochemical
results presenting expression of IL13Rα2 (a), Fra-1 (b) and EphA2 (c) antigens in subsequent populations of astrocytoma cells derived from particular
steps of culture (1–2 months; 3–4 months; 5–7 months). U87MG was used as positive control (d).
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Immunocytochemistry results demonstrated an increase
of the tested proteins level and/or a selection of cell popu-
lations strongly positive for AAAs vs. astrocytoma cells
presenting a lower expression of them and/or admixed
non-tumoural cells. Discrepancies in AAA levels between
glioblastoma xenograft tumours and xenograft-derived
cell lines were also noticed by Wykosky at al., who ex-
plained this phenomenon as a consequence of interaction
with other cellular signalling pathways [7].
The simplest explanation of such a difference is the
proposal that artificial conditions affect the expression
levels of examined genes in vitro; however, such an
approach does not include the phenomenon of cell se-
lection [19,20]. To verify this hypothesis, analyses based
on DNA markers were performed. Molecular anomalies
typical for astrocytomas (TP 53 mutations, EGFR gene
overdosage, CDKN2A deletion; LOH 10p, LOH 10q)
identified in original tumours used for the generation ofcell cultures were applied as potential markers of tu-
mour cells. In accordance with previous reports, EGFR
overdosage resulting from gene amplification was either
almost completely eliminated in vitro or retained in cul-
ture at very low levels. The reasons for this phenomenon
are still under investigation, as it is the possibility of the
retention of this aberration in culture [21-24]. These
facts made doubtful the use of this aberration as a po-
tential marker of tumoural cells in vitro.
Comparative analyses of the loss of heterozygosity on
10p and 10q, CDKN2A deletion and TP53 mutations
suggest the positive selection of the cells harbouring
these anomalies in culture vs. other cells including
possible admixed non-tumoural cells. However, in G111
and G112 cases, we observed that some anomalies
(LOH 10p, LOH 10q) previously identified in initial tu-
mours were not detected in the first stages of cell cul-
ture establishment. We hypothesised that it could be



























Figure 6 Results of comparative analyses of LOH 10q and LOH 10p. The comparative analysis of initial tumours vs. cells collected from particular
stages of culture in relation to the loss of heterozygosity on 10p and 10q. Results of LOH assay visualized by change of the allelic signal intensity in the
tumour sample compared with that in the control (rectangles); NI = non-informative; n.a. = non-analysed.
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lected positively vs. tumour cells at the beginning of
tumour culture generation in vitro [25-27].
Parallel analysis of the examined molecular markers and
AAA expression data revealed that the reduction of AAA
level observed at the beginning of culture was coincident
with a depletion of the cell population harbouring theTable 3 CDKN2A status evaluated with the use of real-time P
Sample G108 G111
Tumour DEL (0.43) DEL (0.17)
1-2 months culture DEL (0.67) DEL (0.35)
3-4 months culture DEL (0.76) DEL (0.00)
5-7 months culture DEL (0.54) DEL (0.02)
Results are presented as relative gene dosage levels in comparison to control (value
demonstrating CDKN2A deletion (details in Methods section). DEL = deletion; n.a. =tested molecular anomalies. Consequently, the increasing
expression of AAAs was accompanied by propagation of
molecular aberrations in culture suggesting the positive
selection of tumoural cells vs. other cell types.
One of the potential options is the presence of GASCs
(GB-associated stromal cells) - a novel population of cells
detected in the glioblastoma microenvironment [28]. OurCR at the DNA level
G112 G113 G114
DEL (0.52) - (0.86) DEL (0.35)
- (1.22) - (1.32) DEL (0.05)
DEL (0.64) - (0.89) DEL (0.00)
DEL (0.00) - (0.95) n.a.
s in brackets). Values ≤ 0.85 were considered as detection of a cell population
non-analysed.
Table 4 EGFR gene dosage status evaluated with the use of real-time PCR
Sample G108 G111 G112 G113 G114
Tumour A/P (18.50) A (6.18) A (9.25) Low A(1.78) Low A (2.02)
1-2 months culture Low A/P (3.58) - (1.12) Low A(1.69) - (1.00) Low A (3.57)
3-4 months culture Low A/P (2.24) Low A (1.58) - (1.02) - (1.31) Low A (2.97)
5-7 months culture Low A/P (1.85) Low A (1.62) Low A (1.68) Low A(1.83) n.a.
Results are presented as relative EGFR gene dosage levels in comparison to control (values in brackets). Values ≥ 5 were considered as EGFR amplification (A);
values 1.5-5 were considered as low amplification level of EGFR (low A). Polysomy 7 (P) were examined based on GPER gene dosage status (details in Methods
section). n.a. = non-analysed.
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did not exclude the possibility that this population of cells
could be expanded periodically vs. astrocytoma cells
in vitro (data not shown). Notwithstanding this hindrance,
in the final stage of culture the positive selection of
tumour cells harbouring aberrations typical for astrocyto-
mas in all the tested samples was observed.
In the majority of cases, the examined molecular
anomalies were reported in original tumours and further
propagated in culture. However, some anomalies were
detected exclusively in culture in the following samples:
G113, G114 – TP53 mutations, G113 – LOH 10p, LOH
10q. Two possibilities are considered here. First, this is
an artifact generated in vitro. Second, these anomalies
were initially present only in a small percentage of cells
in tumour in situ below the level of detection. The latter
seems to be supported by the fact that these anomalies
normally occur in astrocytomas [15,18]. A similar di-
lemma was faced by Solomon et al., who found no evi-
dence of artifactual genetic alterations in tumour cells
caused by ex vivo culture. Moreover, they stressed that
some of these genetic abnormalities had been previously
identified in tumour-derived cell lines and subsequently
their presence were confirmed in vivo [27]. Nickel et al.
also demonstrated that intratumoural heterogeneity may
result in false-negative data for aberrations that appear
only in a minority of cells in a sample [29].
Such reports may contribute to a re-evaluation of the
assumption that tumour-derived cell cultures are a non-
valuable experimental tool, due to the risk of the accu-
mulation of spurious genetic alterations. Moreover, some
studies presented this assertion based on a comparison
of commercially available cell lines vs tumour samples
obtained from other patients [30-33].Table 5 TP 53 mutational status
Sample G108 G111 G
Tumour MT ex 8, c 262, GGT→ GTT WT W
1-2 months culture MT ex 8, c 262, GGT→ GTT WT W
3-4 months culture MT ex 8, c 262, GGT→ GTT WT W
5-7 months culture MT ex 8, c 262, GGT→ GTT WT W
MT =mutation, changes in nucleotide sequences are indicated by arrows; WT = wildIn contrast, Yost et al. reported the utility of previously
validated glioblastoma-derived cultures as pre-clinical
models in defining tumour genetic predictors of drug
response and the escape of tumours from selective pres-
sures (e.g. treatments) [21]. This point of view seems to
be consistent with the findings suggesting that clonal se-
lection is crucial in the recurrence of gliomas that, due
to their intratumoural heterogeneity, often gain resis-
tance to treatment and rapidly recur. Furthermore, the
molecular profiles of recurrent gliomas can be different
from the characteristics of primary tumours resulting in
more aggressive phenotype [34-38]. This scenario seems
to resemble the situation observed in vitro when some
differences between molecular profile of initial tumour
and tumour-derived culture were identified.
Conclusions
Our results revealed that the expression pattern of
astrocytoma-associated antigens in original tumours and
subsequent stages of cell culture is consistent with the
molecular profiles of the examined cell populations. This
finding justifies the utilization of IL13Rα2, Fra-1, and
EphA2 as tools to monitor of the status of astrocytoma-
derived cultures and putative markers of neoplastic cells
presence in vitro. However, the relatively low/moderate
expression of EphA2 in the majority of tested samples
seems to minimize the importance of this antigen as a
potential marker of tumoural cells in vitro.
The results of our long-term experiments demonstrated
a dynamic of changes in cell culture in vitro and revealed
periodical absence/reduction of the selected markers
present initially in a tumour in situ (in three of the five
tested samples). This phenomenon could be caused by
overgrowth of non-tumoural cells in the first stages of112 G113 G114
T WT WT
T MT ex 7; c 245 GGC→ AGC MT ex 7; c 248 CGG→ CAG
T MT ex 7; c 245 GGC→ AGC MT ex 7; c 248 CGG→ CAG
T MT ex 7; c 245 GGC→ AGC n.a.
type; ex = exon; c = codon; n.a. = non-analysed.
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markers at high level was observed indicating the domi-
nation of tumoural cells in the later stages of culture. Our
results suggest that longer culture can reduce the risk of
non-neoplastic cells overgrowth, but at the expense of ini-
tial heterogeneity maintenance. Due to the intratumoural
heterogeneity of high-grade astrocytomas, further molecu-
lar characterisation may be required in order to evaluate
the usefulness of astrocytoma-derived culture as an ex-
perimental model in vitro, dependent on the purpose of
the individual study (e.g. the level of therapeutic targets).
Methods
Astrocytoma cell culture
Tumour samples were obtained from patients who under-
went neurosurgery at the Department of Neurosurgery,
Medical University of Lodz, Poland. All samples were col-
lected under protocols approved by the ethical committee
of the Medical University of Lodz.
Tumour tissue was minced in cell culture media and
passed through a cell strainer (40 μm; BD Falcon™) to ob-
tain a single cell suspension. Cells were washed with PBS
and seeded in T25 cell culture flasks or 6-well plates. Sub-
sequently, the cells were cultured in DMEM/F12 media
supplemented with 10% FBS, 2 mM L-glutamine (PAA),
and antibiotics (Sigma-Aldrich). Depending on prolifera-
tion activity, the cells were passaged to a new culture dish
every 3–10 days and expanded for subsequent analyses.
Further analyses were performed with the use of cells
obtained during three periods of culture - early (1–2
months), middle (3–4 months) and late (5–7 months).
Additionally, U87MG cells were used as a control astrocy-
toma (WHO IV) cell line.
Analyses of molecular markers at DNA level
Quantitative real-time PCR at DNA level - EGFR gene
dosage status
To determine the EGFR gene dosage level in original
tumour tissue and astrocytoma cells in culture, quantitative
real-time PCR was performed using a Rotor-Gene 6000
instrument (Corbett Life Science). The following EGFR
primers were used for amplification: F: AACCATGCCCG
CATTAGCTC; R: AAAGGAATGCAACTTCCCAA.
Each sample was amplified in triplicate in a reaction vo-
lume of 10 μl containing 20 ng of DNA, KAPA SYBR
FAST Universal 2X qPCR Master Mix (Kapa Biosystems)
and forward and reverse primers. The cycling conditions
were performed according to the manufacturer’s protocol.
RNase P was used as a reference gene for normalization of
the target gene dosage level. To confirm the specificity of
the amplification signal, the gene dissociation curve was
considered in each case. Utilizing the method described
previously by Pfaffl et al. [39], the normalized relative
EGFR gene dosage level of the tested samples wascalculated versus the control sample, based on each sam-
ple’s average CT value and each gene’s average PCR effi-
ciency. As a control sample, DNA derived from non-
tumoural tissue (leukocytes) was used, on the assumption
that the gene dosage in normal tissue would be 1. To dis-
tinguish between the amplification of EGFR vs. chromo-
some 7 polysomy, the method described and validated
previously was applied [40]. Briefly, the technique pre-
sented is based on the assumption that the ratio of EGFR
to the other marker located within chromosome 7 (GPER;
7p22) would be equal to 1, if there are no amplicons (as-
suming no LOH within either of the analysed loci). The
following method of result interpretation was applied: the
cumulative EGFR gene dosage was assessed using the ratio
of EGFR to RNaseP (RPP25; 15q24.2); chromosome 7
polysomy was identified when the ratio of GPER to RNa-
seP was higher than 1.5; while EGFR amplification was
identified when the ratio of EGFR to GPER was higher
than 1.5.
Quantitative real-time PCR at DNA level – detection of
CDKN2A deletion
To determine the CDKN2A deletions, quantitative real-
time PCR reactions were performed as described above.
The primer data were based on previous report [40]. The
reference gene was RNaseP. Each sample was analysed
three times. DNA derived from non-neoplastic tissue
(leukocytes) was used as a control. To determine the
threshold value for the tested gene, similar analyses were
performed for 10 samples of DNA obtained from leu-
kocytes. Values equal to/less than 3σ the mean were
considered to represent gene dosage reduction and the
presence of cells presenting gene deletion. Additionally,
the results were verified via agarose gel electrophoresis
using BioRad Quantity One 1-D Analysis Software.
TP53 and IDH1 sequencing analysis
Exons 5–8 of the TP53 gene and exon 4 of the IDH1
gene were amplified by PCR as previously described and
sequenced using the dideoxy termination method and
the SequiTherm Excel DNA Sequencing kit (Epicentre
Technologies) and LiCor automated sequencer accor-
ding to the manufacturer’s protocol. Sequencing analysis
was performed at DNA and cDNA level as described be-
fore [40,41].
LOH assay
LOH analyses were performed using paired tumour speci-
mens and corresponding peripheral blood samples. The
following LOH markers were used: D10S1709, D10S587
(10q); D10S189, D10S1172 (10p). Forward primers were
5′-end fluorescence-labelled. PCR was performed in
thermocycling conditions individually established for each
pair of primers. PCR products were denatured and gel
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was applied to the separation and analysis of PCR-generated
alleles. The analysis of the LOH results was based on the
reduction of the allelic signal intensity in the tumour
sample compared with that in the control.
Expression analysis
Quantitative real-time RT-PCR
Reverse transcription was performed using a QuantiTect
reverse transcription kit (Qiagen) according to the manu-
facturer’s protocol. Real-time PCR was performed using
a RotorGene 6000 instrument (Corbett Life Science).
IL13Rα2, Fra-1, and EphA2-specific primers were used for
amplification of the tested genes (IL-13R2, F ACTGG
TATGAGGGCTTGGAT, R TCTGATGCCTCCAAATA
GGG; Fra-1, F GCCCACTGTTTCTCTTGAGC, R GG
AGATAGGGTTGGGTGGAT; EphA2, F GTGTACA
AGGGCATGCTGAA, R AACTTGTCCAGGGCCCCA
TT). GUSB was used as a reference gene for nor-
malization of the target gene expression level. Each sam-
ple was amplified in triplicate in a reaction volume of
10 μl containing 20 ng of cDNA, KAPA SYBR FAST
Universal 2X qPCR Master Mix (Kapa Biosystems) and
forward and reverse primers. The cycling conditions were
performed according to the manufacturer’s protocol. To
confirm the specificity of the amplification signal, the gene
dissociation curve was considered in each case. Norma-
lized relative expression levels for the examined genes in
the tested samples versus the control sample were calcu-
lated utilizing the method described previously by Pfaffl
et al., based on each sample’s average CT value and each
gene’s average PCR efficiency [39]. RNA derived from a
normal human brain (Total RNA, Brain, Human; Agilent
Technologies) was used as a control.
RT-PCR
Reverse transcription was performed using QuantiTect
reverse transcription kit (Qiagen) according to the ma-
nufacturer’s protocol. The conventional RT-PCR was ap-
plied to examine the tested tumour samples in terms of
EGFRvIII expression. The results were obtained with the
use of two pairs of primers described previously [42],
and visualized on agarose gel; RNA derived from tumour
tissue positive for EGFRvIII was used as a control.
Immunocytochemistry
For immunocytochemical analysis, cell cultures were
fixed for 15 min in 4% paraformaldehyde in PBS (and
permeabilized with 0.1% Triton X-100 for 10 min, if
necessary). Non-specific binding sites were blocked with
2% donkey serum in PBS for 1 h. Subsequently, the cells
were incubated for 1 h with the following antibodies:
anti-IL13 receptor alpha 2 (ab55275, Abcam); anti-Fra-1
(sc-605, Santa Cruz Biotech.); anti-EphA2 (sc-924, SantaCruz Biotech.). For visualization, the appropriate species-
specific fluorochrome-conjugated secondary antibodies
(1:500, donkey anti-rabbit AlexaFluor488, 1:500, donkey
anti-mouse Alexa-Fluor594; Molecular Probes) were ap-
plied for 1 h in the dark. Controls, with secondary anti-
bodies alone and with matched isotype controls in place of
primary antibodies, were processed in the same manner.
Slides were mounted with ProLongGold Antifade Reagent
with DAPI (Molecular Probes), coverslipped and examined
using an Olympus BX-41 fluorescence microscope.
Immunohistochemistry
For immunohistochemistry 5-um thick sections of forma-
lin-fixed and paraffin-embedded tissue were used with the
following antibodies: anti-IL13 receptor alpha 2 (1 μg/ml;
ab55275, Abcam), anti-Fra-1 (1:200; sc-28310, Santa Cruz
Biotech.). Epitope retrieval method included citrate buffer
pH 9 and microwave heating for Fra-1 analysis and citrate
buffer pH 9 with water bath heating for IL13Rα2 detection.
For visualization Dako EnVision + System-HRP (DAB)
for Use with Mouse Primary Antibodies, (K4007) kit was
used. Negative controls were paralleled sections treated
as above with omission of the primary antibody.
Statistical analysis
The real-time PCR data were expressed as means ± SD.
The data for initial tumour samples were analyzed with
the use of the Student t test. For further analyses, when
more than two groups were compared, the Kruskal–Wallis
test was used initially to identify a difference and, if this
proved significant, individual groups were further investi-
gated using the Conover–Inman posthoc test. In all tests,
P < 0.05 was considered significant.
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